PharmaVoice
AUGUST 29, 2023
The CEO of Cullinan Oncology is taking a small biotech to the next step and believes the temporary financial barriers are smaller than scientific progress.
Fierce Pharma
AUGUST 30, 2023
After 16 years on the market, Takeda's blockbuster attention-deficit/hyperactivity disorder (ADHD) med Vyvanse has finally reached its patent cliff. | After 16 years on the market, Takeda's blockbuster ADHD med Vyvanse has finally reached its patent cliff. And the FDA's approval of several generics comes amid a U.S. shortage of the drug.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
AUGUST 28, 2023
In a new lawsuit, Bon Secours Mercy Health Virginia alleges that Anthem Health Plans of Virginia owes the health system more than $93 million in outstanding unpaid and underpaid claims. The post Bon Secours Mercy Health Sues Anthem Health Plans of Virginia for Unpaid Claims appeared first on Above the Law.
PharmaTimes
SEPTEMBER 1, 2023
The AI platform and expertise will be combined to discover novel targets for haematological cancers - News - PharmaTimes
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
European Pharmaceutical Review
AUGUST 31, 2023
New research published in the New England Journal of Medicine has indicated that stem cell gene therapy could provide a curative treatment for sickle cell disease (SCD). Based on new data from the Novartis Phase I/II clinical trial , which used the first therapy to target a new genetic area and use cryopreserved stem cells, trial participants reported a decrease in vaso-occlusive events.
Fierce Pharma
AUGUST 30, 2023
Last month, during a quarterly conference call—as Johnson & Johnson considered its future beyond the separation of its consumer health unit—Chief Financial Officer Joe Wolk described the compan | Last month, during a quarterly conference call—as Johnson & Johnson considered its future beyond separation of its consumer health unit—Chief Financial Officer Joe Wolk described the company’s appetite for M&A as “voracious.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
PharmaTimes
SEPTEMBER 1, 2023
Partnership will discover and develop novel antibodies for a range of autoimmune diseases - News - PharmaTimes
European Pharmaceutical Review
SEPTEMBER 1, 2023
The global mRNA-based oncology therapy market is expected to reach $2 billion by 2029, according to GlobalData. BioNTech is anticipated to lead the market with a predicted $885 million in sales, and a 44.6 percent share by 2029, the research has shown. Global mRNA-based oncology therapy market At present, the pharmaceutical industry is still awaiting the first regulatory approval of an mRNA-based oncology therapy. mRNA stability and delivery specificity are two of the main obstacles hindering pr
Fierce Pharma
SEPTEMBER 1, 2023
After months of legal wrangling, Amgen is free to go forward with its $27.8 billion buyout of Horizon Therapeutics. | Friday, the U.S. Federal Trade Commission (FTC) said it reached a proposed consent order with Amgen to address “the potential competitive harm” that could result from the merger deal. Now, Amgen is free to go forward with its $28 billion buyout.
MedCity News
AUGUST 31, 2023
During past recessions, the healthcare sector remained relatively immune to economic downswings — but things are different now that a sweeping labor shortage and lower patient volumes have been added to the mix.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
PharmaTimes
AUGUST 31, 2023
The therapy is used to treat patients with psoriatic arthritis and axial spondyloarthritis - News - PharmaTimes
Pharmaceutical Technology
SEPTEMBER 1, 2023
Novo Nordisk's obesity drugs are driving Danish growth as well as record profits as the company becomes second-most valuable in Europe.
Fierce Pharma
AUGUST 30, 2023
Even without an FDA approval, Roche’s cancer drug Avastin is widely used by doctors to treat certain eye diseases. | Even without an FDA approval, Roche’s cancer drug Avastin is widely used by doctors to treat certain eye diseases. Outlook Therapeutics has been trying to get an official approval for a reformulated version, but instead got a rejection letter.
MedCity News
AUGUST 30, 2023
Novo Nordisk is expanding its cardiometabolic drug pipeline with the acquisition of Embark Biotech, a startup developing drugs for a novel target that can suppress appetite and boost calorie burning in cells. Embark’s science comes University of Copenhagen research on a novel fat cell target.
PharmaTimes
AUGUST 31, 2023
The candidate is a peripherally restricted small-molecule PDE10 inhibitor to treat ulcerative colitis - News - PharmaTimes
PharmaVoice
SEPTEMBER 1, 2023
Psycheceutical is developing a back-of-the-neck topical treatment for ketamine but believes the delivery route holds promise for far more drugs.
Fierce Pharma
SEPTEMBER 1, 2023
Approved two summers ago for chronic kidney disease (CKD) associated with type 2 diabetes, Bayer’s Kerendia (finerenone) isn’t off to the flying start expected of a potential blockbuster. | Bayer plans three new trials to assess its potential blockbuster medicine Kerendia in heart failure. The drug was first approved 2 years ago in CKD associated with diabetes.
MedCity News
AUGUST 29, 2023
A study on BeMe Health, a behavioral health platform for teens, found that users engaged with the platform eight times on average over a month. The study was done in collaboration with Stanford University.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
European Pharmaceutical Review
AUGUST 30, 2023
The Windsor Framework, announced on 9 June 2023 by the Medicines and Healthcare products Regulatory Agency (MHRA), provides a long-term solution for the supply of medicines into Northern Ireland. The agreement stipulates that certain conditions must be met in the labelling and packaging of these medicinal products. In preparation for the implementation of these requirements under the Windsor Framework, new guidance for the industry was published by the MHRA on 28 July 2023.
Pharmaceutical Commerce
AUGUST 30, 2023
Event’s first session aims to analyze the legislation’s implementation, as FDA enforcement is delayed until November 2024.
Fierce Pharma
SEPTEMBER 1, 2023
After a groundbreaking approval for Tecentriq, Roche has another positive early-stage lung cancer trial to celebrate. This time, the honor belongs to a targeted therapy in Alecensa. | After a groundbreaking approval for Tecentriq, Roche has another positive early-stage lung cancer trial to celebrate. This time, the honor belongs to a targeted therapy in Alecensa.
MedCity News
AUGUST 31, 2023
When real-life failure is not an option, practicing curated, trial-and-error simulations in VR can reduce patient risk in high-acuity scenarios. With nursing faculty also in short supply and a wave rapidly approaching retirement age, virtual reality simulations can help bridge the gap between learners needing supervised clinical experiences, and time-pressed preceptors, who have their own patients to care for in addition to guiding novices in clinical settings.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Pharmaceutical Technology
AUGUST 31, 2023
Novo Nordisk has acquired Embark Biotech and its lead asset targeting obesity and other cardiometabolic diseases.
Medgadget
AUGUST 30, 2023
Researchers at New York University have developed a new method to target many viruses that cause disease. For viruses with a lipid membrane, which includes many that commonly cause disease, this new technique could prove to be fatal. By targeting the lipid membrane, the approach may circumvent the treatment resistance that arises when viruses mutate to alter their surface proteins, which are the most common targets for conventional anti-viral drugs.
Fierce Pharma
AUGUST 31, 2023
Seven weeks after saying it would allow generic competition for drug-resistant tuberculosis (TB) treatment Sirturo (bedaquiline) in low- and middle-income countries (LMICs), Johnson & Johnson h | Seven weeks after saying it would allow generic competition for drug-resistant tuberculosis (TB) treatment Sirturo (bedaquiline) in low- and middle-income countries (LMICs), Johnson & Johnson has slashed its own drug's price by 55% to $130 for a six-month course.
MedCity News
AUGUST 30, 2023
Kidney care company Strive Health announced last week that it is collaborating with primary care company Oak Street Health to serve Medicare members with stage 4 chronic kidney disease and end-stage kidney disease.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
Pharmaceutical Technology
SEPTEMBER 1, 2023
Otsuka Pharmaceutical has signed a definitive arrangement agreement to acquire Mindset Pharma, in an all-cash deal worth C$80m ($59.1m).
European Pharmaceutical Review
AUGUST 31, 2023
In the wake of the COVID-19 pandemic, we have now acquired a much clearer understanding of how fast a virus spreads. Even with extremely rapid vaccine development, limitations in production capabilities can have real-life implications. This has led pharmaceutical equipment manufacturers to react quickly, while maintaining due levels of diligence and social responsibility.
Fierce Pharma
AUGUST 30, 2023
After a tumultuous year of manufacturing hiccups, executive turnover and dwindling revenues, Catalent is handing the reins to activist investor Elliott Management. | After a tumultuous year of manufacturing hiccups, executive turnover and dwindling revenues, Catalent is linking up with Elliott Management. The CDMO giant struck a cooperation agreement with the activist investor group as it announced fourth-quarter revenues and unveiled a sweeping governance shakeup.
MedCity News
SEPTEMBER 1, 2023
As the value-based care market gets more crowded, startups in this space will have to nail down the fundamentals in order to attract capital from investors, healthcare business expert Paul Campbell said during a virtual conference. He encouraged startups to be crystal clear about what their value proposition is for three main stakeholders — patients, providers and payers.
Expert insights. Personalized for you.
105 
Let's personalize your content